Research Topics
| Julye C LavoieSummaryAffiliation: British Columbia Country: Canada Publications
| Collaborators
|
Detail Information
Publications
High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in VancouverJulye C Lavoie
Leukemia Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada
Blood 106:1473-8. 2005..HD-ASCT can lead to durable remissions in relapsed or refractory HL with acceptable but definite late toxicity. The occurrence of late events necessitates lifelong medical surveillance...- Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphomaRichard T Doocey
Division of Hematology, Leukemia/Bone Marrow Transplant Program of British Columbia, The Vancouver Hospital and Health Science Centre, Vancouver, BC, Canada
Br J Haematol 131:223-30. 2005..In conclusion, allo-SCT for relapsed or refractory aggressive histology NHL results in long-term EFS and OS of 40-50%. Patients with chemorefractory disease can have a durable remission post-transplant... - IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantationThomas J Nevill
The Leukemia BMT Program of British Columbia, Division of Hematology, Vancouver General Hospital, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada
Biol Blood Marrow Transplant 15:205-13. 2009..001). SCT outcomes in MDS/sAML are strongly associated with the IPSS cytogenetic risk group, although the use of BSC in poor-risk karyotype patients may lead to a more favorable long-term EFS... - Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamideAsha Johny
The Leukemia/Bone Marrow Transplantation Program of British Columbia, Vancouver, British Columbia, Canada
Biol Blood Marrow Transplant 12:480-9. 2006..03). VP/Cy is able to induce CR1 in most patients with primary refractory AL with an acceptable toxicity profile. Subsequent allogeneic SCT can lead to long-term EFS in a significant proportion of patients... - Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myelomaJohn Kuruvilla
The Leukemia Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada
Biol Blood Marrow Transplant 13:925-31. 2007..Myeloablative alloSCT should not be considered standard treatment, and should only be considered in the context of a clinical trial... - Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remissionKevin W Song
The Leukemia Bone Marrow Transplantation Program of British Columbia, Vancouver Hospital and Health Sciences Center, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada
Leuk Lymphoma 46:525-31. 2005..5-63.9); unknown 2.3 (0.6-8.8) (P=0.028). We conclude that patients with AML in CR2 who undergo autotransplant can have durable remissions and those with a good risk karyotype are the most likely to obtain long-term disease-free survival... - Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levelsDonna L Forrest
Leukemia BMT Program of British Columbia, Division of Hematology, Vancouver General Hospital, British Columbia Cancer Agency and University of British Columbia, Vancouver, BC, Canada
Leuk Res 33:271-5. 2009..8 (95% CI 2.2-53.5) and 6.4 (95% CI 1.4-29.4), respectively. Furthermore, a longer duration of IM therapy also was associated with a greater likelihood of achieving MMR (P=.02)... - Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factorsYulia Lin
The Leukemia/BMT Program of British Columbia, The Division of Hematology, 950 West 10th Avenue, Room 3300, Vancouver, British Columbia V5Z 4E3, Canada
Cancer Genet Cytogenet 170:16-23. 2006..Therefore, while the development of Ph-negative clonal hematopoiesis in patients with CML treated with IM is uncommon, it appears to be more frequent than that previously seen with IFN, but it does not seem to confer a worse prognosis... - Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantationCynthia L Toze
Division of Hematology, Leukemia BMT Program of British Columbia, Vancouver Hospital and Health Sciences Centre, Vancouver, British Columbia, Canada
Br J Haematol 127:311-21. 2004..Allogeneic BMT has resulted in long-term disease-free survival for approximately 50% of this cohort of patients with advanced follicular lymphoma and most of them now enjoy robust health... - High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hemDonna L Forrest
Leukemia Bone Marrow Transplant Program of British Columbia, Canada
J Clin Oncol 23:7994-8002. 2005.... - Correlation between karyotype and quantitative immunophenotype in acute myelogenous leukemia with t(8;21)Haytham Khoury
Department of Cellular and Molecular Biology, Princess Margaret Hospital, Toronto, Ontario, Canada
Mod Pathol 17:1211-6. 2004..1 x 10(3)) had a sensitivity, specificity and positive predictive value of 100%. These aberrant phenotypic patterns might help identify patients with t(8;21) at diagnosis and could be useful in minimal residual disease monitoring...